SCHEMBL17619487

SCHEMBL17619487

CN1CCN(CCn2cc(-c3ccccc3)c(N)n2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.46
KDR P35968 2/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
SIGMAR1 Q99720 3/20 0.43
MC4R P32245 1/20 0.41
CHKA P35790 1/20 0.40
HRH4 Q9H3N8 3/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2576720 0.87 CYP1A2 (0.49) KDM4EALDH1A1POLBSIGMAR1HRH4
Hydrochloric Acid SCHEMBL2578543 0.86 CYP1A2 (0.48) RAB9AKDM4EALDH1A1POLBSIGMAR1
SCHEMBL19450178 0.86 PLK1 (0.47) NPC1RAB9AKDM4EALDH1A1POLB
SCHEMBL17610325 0.83 MAPT (0.38) FGFR1KDRNPC1RAB9AALDH1A1
SCHEMBL19456012 0.82 CHKA (0.45) FGFR1KDRNPC1RAB9AMC4R
SCHEMBL17619451 0.75 MAPT (0.41) NPC1RAB9AKDM4EALDH1A1ADORA2A
SCHEMBL17619688 0.74 PTGIR (0.41) NPC1RAB9AKDM4EALDH1A1SIGMAR1
SCHEMBL17619532 0.72 SMN1; SMN2 (0.43) KDRNPC1RAB9AALDH1A1POLB
SCHEMBL17619488 0.72 SMN1; SMN2 (0.48) FGFR1KDRNPC1RAB9AKDM4E
SCHEMBL2582105 0.71 CYP1A2 (0.47) KDM4EALDH1A1POLBCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170291890-A1 HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF Epizyme, Inc. 2017-10-12 US disclosed
US-20170291890-A1 HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF Epizyme, Inc. 2017-10-12 US disclosed
WO-2016044666-A1 HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF Epizyme, Inc. (US) 2016-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291890-A1 HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF HCCS, TP53, NME2 FGFR1 3501/4885KDR 2666/4885NPC1 2481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.